Announces

Aytu BioScience Announces Pricing of $7.5 Million Public Offering of Common …
Aytu's current portfolio of commercial and late-stage urology products addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction, and the company plans to expand into other urological indications for which there ... [...]
6
Like
Save
Immunomedics Announces Abstract on Sacituzumab Govitecan (IMMU-132) in …
IMMU-132 has received Breakthrough Therapy Designation from FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease. Immunomedics has a research collaboration with Bayer to ... [...]
1
Like
Save
WCM announces collaboration with J & J Innovation to investigate new cancer …
... the preclinical efficacy of combining external-beam radiotherapy with Janssen's immuno-oncology drugs with the ultimate goal of translating findings into clinical trials to benefit patients with various types of solid tumors, including prostate and ... [...]
7
Like
Save
TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement …
“This innovative, indication-specific collaboration accelerates efforts to expand the treatment options available for men with prostate cancer and further increases the value of the niraparib franchise.” ... To the extent that statements contained in ... [...]
7
Like
Save
CymaBay Therapeutics Announces Acceptance of Arhalofenate Phase 2b Gout Study …
/EIN News/ -- NEWARK, Calif., March 28, 2016 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), today announced the online publication of its Phase 2b study of arhalofenate, a novel dual-acting product candidate for the treatment of ... [...]
7
Like
Save
OPKO Health Announces Dosing of First Subject in Phase 1 Clinical Study of a …
... Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office ... [...]
1
Like
Save
EDAP Announces Sylvester Comprehensive Cancer Center in Miami as First …
EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) for prostate tissue ablation in the U.S. and for treatment of localized prostate cancer in the rest of the world. HIFU treatment is shown to be a minimally invasive and ... [...]
6
Like
Save
Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 …
With no approved therapy for the treatment of brain metastases, options for this patient population are currently limited,” said Erika Hamilton, M.D., director, Breast and Gynecologic Cancer Research Program, Sarah Cannon Research Institute. “This ... [...]
5
Like
Save
Sen. Claire McCaskill announces she has breast cancer
“Most women with cancer detected mammographically are going to have Stage 1,” said Mike Naughton, associate professor of medicine at Washington University's Siteman Cancer Center. He said that would normally entail surgery and radiation treatment, ... [...]
2
Like
Save
Ferring announces the start of the PRONOUNCE Trial for patients with advanced …
Prostate cancer is the second most common form of cancer in men worldwide with 1.1 million cases diagnosed and over 300,000 deaths in 2012.1 Androgen deprivation therapy (ADT) is considered the gold-standard treatment for patients with advanced ... [...]
7
Like
Save
Pan Am Cancer Treatment Center Announces Availability Of ImmunoMax For …
... plant origin) that has proved its capacity to stimulate natural killer cells and has been on the Russian market for about 13 years to provide treatment for both bacterial and viral infections, and also proved to reduce PSA levels in patients with ... [...]
4
Like
Save
Fine Treatment Announces BPH and Prostate Treatment & How to Treat Prostate …
Fine Treatment gives amazing tips on how prostate can be treated at home from Benign Prostatic Hyperplasia (BPH) and prostatitis without supplements, drugs, laser therapy or other operations by using natural devices invented by Dr Allen. This prostate ... [...]
1
Like
Save
Radius Health Inc.: Radius Health Announces Clinical Collaboration With a …
RAD1901 is a selective estrogen receptor down-regulator/degrader, or SERD, which at high doses has potential for use as an oral non-steroidal treatment for hormone-driven, or hormone-resistant, metastatic breast cancer. RAD1901 is currently being ... [...]
5
Like
Save
Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical …
RAD1901 is a selective estrogen receptor down-regulator/degrader, or SERD, which at high doses has potential for use as an oral non-steroidal treatment for hormone-driven, or hormone-resistant, metastatic breast cancer. RAD1901 is currently being ... [...]
3
Like
Save
BioPlus Specialty Pharmacy Announces Cosentyx® Now Available For Expanded …
Psoriatic arthritis and ankylosing spondylitis are both associated with painful inflammation of joints and the spine; without treatment patients can suffer permanent joint or bone damage. “Cosentyx was previously approved for treating moderate-to ... [...]
5
Like
Save
Diplomat Announces COSENTYX® Availability for the Treatment of Two New Indications
"The two new approved indications are a real turning point for those living with ankylosing spondylitis and psoriatic arthritis–offering a new approach to treating two of the most common inflammatory joint conditions." COSENTYX® is manufactured by ... [...]
7
Like
Save